Нутрицевтики в виде БАД в лечении ожирения у детей: мифы и реальность

Ожирение в детском возрасте — важная медико-социальная проблема, в том числе в связи с развитием метаболических осложнений, хронического низкоинтенсивного воспаления, а также инсулинорезистентности — ключевого фактора метаболического синдрома. В этом контексте актуальным остается поиск безопасных и эффективных методов профилактики и терапии детского ожирения. Эффективность комплексной терапии ожирения может быть повышена применением нутрицевтиков — пищевых добавок с доказанным положительным влиянием на здоровье. В обзоре проанализирован широкий спектр нутрицевтиков (омега-3 полиненасыщенные жирные кислоты, пробиотики, инозитолы, берберин, дииндолилметан и др.), механизмов их действия, показателей эффективности и безопасности, особенностей применения.

1. Каннер Е.В., Максимов М.Л., Каннер И.Д., Горелов А.В. Дефицит витамина D у детей с ожирением: следствие или причина? // РМЖ. Медицинское обозрение. — 2022. — Т. 6. — № 9. — С. 516-522. — doi: https://doi.org/10.32364/2587-6821-2022- 6-9-516-522

2. Frithioff-Bojsoe C, Lund MAV, Lausten-Thomsen U, et al. Leptin, adiponectin, and their ratio asmarkers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr Diabetes. 2020;21(2):194-202. doi: https://doi.org/10.1111/pedi.12964

3. Marcus C, Danielsson P Hagman E. Pediatric obesity-Longterm consequences and effect of weight loss. J Intern Med. 2022;292(6):870-891. doi: https://doi.org/10.1111/joim.13547

4. Pkhaladze L, Barbakadze L, Kvashilava N. Myoinositol in the Treatment of Teenagers Affected by PCOS. Int J Endocrinol. 2016;2016:1473612. doi: https://doi.org/10.1155/2016/1473612

5. Васюкова О.В., Окороков П.Л., Малиевский О.А. и др. Клинические рекомендации «Ожирение у детей» // Ожирение и метаболизм. — 2024. — Т. 21. — № 4. — С. 439-453. — doi: https://doi.org/10.14341/omet13194

6. Wu S, Zhu C, Wang Z, et al. Effects of Fish Oil Supplementation on Cardiometabolic Risk Factors in Overweight or Obese Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials. Front Pediatr. 2021;9:604469. doi: https://doi.org/10.3389/fped.2021.604469

7. Li Y, Liu T, Qin L, Wu L. Effects of probiotic administration on overweight or obese children: a meta-analysis and systematic review. J Transl Med. 2023;21(1):525. doi: https://doi.org/10.1186/s12967-023-04319-9

8. Virgolici B, Popescu LA, Virgolici HM, et al. Effects of omega-3 fatty acids associated with antioxidant vitamins in overweight and obese children. Acta Endocrinol (Buchar). 2023;19(2):221-227. doi: https://doi.org/10.4183/aeb.2023.221

9. European Food Safety Authority (EFSA). Dietary Reference Values for nutrients Summary report. EFSA Supporting Publications. 2017;14(12):23. doi: https://doi.org/10.2903/sp.efsa.2017. e15121

10. van der Wurff ISM, Meyer BJ, de Groot RHM. Effect of Omega-3 Long Chain Polyunsaturated Fatty Acids (n-3 LCPUFA) Supplementation on Cognition in Children and Adolescents: A Systematic Literature Review with a Focus on n-3 LCPUFA Blood Values and Dose of DHA and EPA. Nutrients. 2020;12(10):3115. doi: https://doi.org/10.3390/nu12103115

11. Khorshidi M, Hazaveh ZS, Alimohammadi-Kamalabadi M, et al. Effect of omega-3 supplementation on lipid profile in children and adolescents: a systematic review and meta-analysis of randomized clinical trials. Nutr J. 2023;22(1):9. doi: https://doi.org/10.1186/s12937-022-00826-5

12. Chang JP Tseng PT, Zeng BS, et al. Safety of Supplementation of Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2023;14(6):1326-1336. doi: https://doi.org/10.1016/j.advnut.2023.08.003

13. Jones RB, Alderete TL, Martin AA, et al. Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial. Pediatr Obes. 2018;13(11):705-714. doi: https://doi.org/10.1111/ijpo.12273

14. Million M, Angelakis E, Paul M, et al. Comparative meta-analysis of the effect of lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53(2):100-108. doi: https://doi.org/10.1016/j.micpath.2012.05.007

15. Larsen N, Vogensen FK, Gobel RJ, et al. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin Nutr. 2013;32(6):935-940. doi: https://doi.org/10.1016/j.clnu.2013.02.007

16. Zalewski BM, Szajewska H. No Effect of Glucomannan on Body Weight Reduction in Children and Adolescents with Overweight and Obesity: A Randomized Controlled Trial. J Pediatr. 2019;211: 85-91.e1. doi: https://doi.org/10.1016/j.jpeds.2019.03.044

17. Duan Y, Wang L, Ma Y et al. A meta-analysis of the therapeutic effect of probiotic intervention in obese or overweight adolescents. Front Endocrinol (Lausanne). 2024;15:1335810. doi: https://doi.org/10.3389/fendo.2024.1335810

18. Robertson C, Savva GM, Clapuci R, et al. Incidence of necrotising enterocolitis before and after introducing routine prophylactic Lactobacillus and Bifidobacterium probiotics. Arch Dis Child Fetal Neonatal Ed. 2020;105(4):F380-F386. doi: https://doi.org/10.1136/archdischild-2019-317346

19. Pkhaladze L, Russo M, Unfer V, et al. Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives. Eur Rev Med Pharmacol Sci. 2021;25(23): 7476-7485. doi: https://doi.org/10.26355/eurrev_202112_27447

20. Antoniotti V, Partenope C, Solito A, et al. Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity. Diabetes Obes Metab. 2025;27(4):1932-1939. doi: https://doi.org/10.1111/dom.16185

21. Sairally BZF, Dhillon-Smith RK, Jethwani G, Latthe P Myoinositol or D-chiro-inositol for PCOS symptoms in adolescents: a narrative review. J Pediatr Endocrinol Metab. 2023;37(2):91-101. doi: https://doi.org/10.1515/jpem-2023-0458

22. Phelps D, Ward R, Williams R, et al. Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res. 2016;80(2):209-217. doi: https://doi.org/10.1038/pr.2016.97

23. Bizzarri M, Fuso A, Dinicola S, et al. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016;12(10):1181-1196. doi: https://doi.org/10.1080/17425255.2016.1206887

24. DiNicolantonio JJ, H O'Keefe J. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9(1):e001989. doi: https://doi.org/10.1136/openhrt-2022-001989

25. Rojas J, Arraiz N, Aguirre M, et al. AMPK as Target for Intervention in Childhood and Adolescent Obesity. J Obes. 2011;2011:252817. doi: https://doi.org/10.1155/2011/252817

26. Guo J, Chen H, Zhang X, et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid Med Cell Longev. 2021;2021:2074610. doi: https://doi.org/10.1155/2021/2074610

27. Yang H, Seo SG, Shin SH, et al. 3,3-Diindolylmethane suppresses high-fat diet-induced obesity through inhibiting adipogenesis of pre-adipocytes by targeting USP2 activity. Mol Nutr Food Res. 2017;61(10). doi: https://doi.org/10.1002/mnfr.201700119

28. Liu YF, Wang HH, Geng YH, et al. Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism. Front Pharmacol. 2023;14:1112088. doi: https://doi.org/10.3389/fphar.2023.1112088

29. Suciu I, Delp J, Gutbier S, et al. Definition of the Neurotoxicity- Associated Metabolic Signature Triggered by Berberine and Other Respiratory Chain Inhibitors. Antioxidants (Basel). 2023;13(1):49. doi: https://doi.org/10.3390/antiox13010049

30. Li Z, Wang Y Xu Q, et al. Berberine and health outcomes: An umbrella review. Phytother Res. 2023;37(5):2051-2066. doi: https://doi.org/10.1002/ptr.7806

31. Fogacci F, ALGhasab NS, Di Micoli V, et al. CholesterolLowering Bioactive Foods and Nutraceuticals in Pediatrics: Clinical Evidence of Efficacy and Safety. Nutrients. 2024;16(10):1526. doi: https://doi.org/10.3390/nu16101526

32. Xiong P Niu L, Talaei S, et al. The effect of berberine supplementation on obesity indices: A dose-response meta-analysis and systematic review of randomized controlled trials. Complement Ther Clin Pract. 2020;39:101113. doi: https://doi.org/10.1016/j.ctcp.2020.101113

33. Ilyas Z, Perna S, Al-Thawadi S, et al. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother. 2020;127:110137. doi: https://doi.org/10.1016/j.biopha.2020.110137

34. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-292. doi: https://doi.org/10.1016/j.metabol.2009.07.029

35. Yu M, Jin X, Liang C, et al. Berberine for diarrhea in children and adults: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2020;13:1756284820961299. doi: https://doi.org/10.1177/1756284820961299

36. Wang H, Zhu C, Ying Y, et al. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget. 2017;9(11):10135-10146. doi: https://doi.org/10.18632/oncotarget.20807

37. Malhotra B, Kulkarni GT, Dhiman N, et al. Recent advances on Berberis aristata emphasizing berberine alkaloid including phytochemistry, pharmacology and drug delivery system. J Herb Med. 2021;27:100433. doi: https://doi.org/10.1016/j.hermed.2021.100433

38. Amare DE. Anti-cancer and other biological effects of a dietary compound 3,3'-diindolylmethane supplementation: a systematic review of human clinical trials. Nutrition and Dietary Supplements. 2020;12:123-137. doi: https://doi.org/10.2147/NDS.S261577

39. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2): e202206064. doi: https://doi.org/10.1542/peds.2022-060640

40. El Amrousy D, El-Afify D. Effects of alpha lipoic acid as a supplement in obese children and adolescents. Cytokine. 2020;130:155084. doi: https://doi.org/10.1016/j.cyto.2020.155084

41. de Ligt M, Timmers S, Schrauwen P Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochim Biophys Acta. 2015;1852(6):1137-1144. doi: https://doi.org/10.1016/j.bbadis.2014.11.012

42. Hillsley A, Chin V, Li A, McLachlan CS. Resveratrol for Weight Loss in Obesity: An Assessment of Randomized Control Trial Designs in ClinicalTrials.gov. Nutrients. 2022;14(7):1424. doi: https://doi.org/10.3390/nu14071424

43. Xinmei Xu, Huan Yi, Jiasi Wu, et al. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother. 2021;133:110984. doi: https://doi.org/10.1016/j.biopha.2020.110984

44. Mohammadpour S, Reza Amini M, Shahinfar H, et al. Effects of glucomannan supplementation on weight loss in overweight and obese adults: A systematic review and meta-analysis of randomized controlled trials. Obesity Medicine. 2020;19:100276. doi: https://doi.org/10.1016/j.obmed.2020.100276